Mankind Pharma and Innovent Biologics partner to license and commercialise Sintilimab EP News Bureau Dec 26, 2024 Sintilimab, marketed as TYVY (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody…
Lilly issues Complete Response Letter for Sintilimab in combination with Pemetrexed and Platinum… EP News Bureau Mar 25, 2022 The letter indicates that the review cycle is complete but the FDA is unable to approve the application in its current form,…
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of… EP News Bureau Jan 24, 2022 The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per…
